Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA – Get Rating) has been given an average rating of “Buy” by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $18.14.
Several research firms have commented on AYLA. Maxim Group dropped their price target on shares of Ayala Pharmaceuticals from $22.00 to $12.00 in a research note on Wednesday, March 30th. Oppenheimer lowered their target price on shares of Ayala Pharmaceuticals from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Wednesday, March 30th. Finally, Raymond James lowered their target price on shares of Ayala Pharmaceuticals from $24.00 to $6.00 and set an “outperform” rating for the company in a research note on Wednesday, March 30th.
Institutional investors and hedge funds have recently made changes to their positions in the stock. DLD Asset Management LP raised its holdings in shares of Ayala Pharmaceuticals by 9.2% in the first quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock valued at $688,000 after buying an additional 14,635 shares during the last quarter. CSS LLC IL acquired a new position in shares of Ayala Pharmaceuticals during the fourth quarter worth about $131,000. Wellington Management Group LLP increased its stake in shares of Ayala Pharmaceuticals by 36.5% during the third quarter. Wellington Management Group LLP now owns 961,609 shares of the company’s stock worth $10,905,000 after acquiring an additional 257,246 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Ayala Pharmaceuticals by 406,248.7% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,153,648 shares of the company’s stock worth $18,328,000 after acquiring an additional 2,153,118 shares during the period. 56.07% of the stock is owned by hedge funds and other institutional investors.
Ayala Pharmaceuticals (NASDAQ:AYLA – Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.05. The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $0.88 million. Ayala Pharmaceuticals had a negative net margin of 1,403.90% and a negative return on equity of 115.40%. On average, sell-side analysts anticipate that Ayala Pharmaceuticals will post -2.55 earnings per share for the current fiscal year.
Ayala Pharmaceuticals Company Profile (Get Rating)
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
- Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (AYLA)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.